Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Greece.
Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Greece.
J Autoimmun. 2019 Nov;104:102347. doi: 10.1016/j.jaut.2019.102347. Epub 2019 Oct 11.
Thrombosis in the context of Cardiovascular disease (CVD) affects mainly the blood vessels supplying the heart, brain and peripheries and it is the leading cause of death worldwide. The pathophysiological thrombotic mechanisms are largely unknown. Heritability contributes to a 30% of the incidence of CVD. The remaining variation can be explained by life style factors such as smoking, dietary and exercise habits, environmental exposure to toxins, and drug usage and other comorbidities. Epigenetic variation can be acquired or inherited and constitutes an interaction between genes and the environment. Epigenetics have been implicated in atherosclerosis, ischemia/reperfusion damage and the cardiovascular response to hypoxia. Epigenetic regulators of gene expression are mainly the methylation of CpG islands, histone post translational modifications (PTMs) and microRNAs (miRNAs). These epigenetic regulators control gene expression either through activation or silencing. Epigenetic control is mostly dynamic and can potentially be manipulated to prevent or reverse the uncontrolled expression of genes, a trait that renders them putative therapeutic targets. In the current review, we systematically studied and present available data on epigenetic alterations implicated in thrombosis derived from human studies. Evidence of epigenetic alterations is observed in several thrombotic diseases such as Coronary Artery Disease and Cerebrovascular Disease, Preeclampsia and Antiphospholipid Syndrome. Differential CpG methylation and specific histone PTMs that control transcription of prothrombotic and proinflammatory genes have also been associated with predisposing factors of thrombosis and CVD, such us smoking, air pollution, hypertriglyceridemia, occupational exposure to particulate matter and comorbidities including cancer, Chronic Obstructive Pulmonary Disease and Chronic Kidney Disease. These clinical observations are further supported by in vitro experiments and indicate that epigenetic regulation affects the pathophysiology of thrombotic disorders with potential diagnostic or therapeutic utility.
心血管疾病(CVD)背景下的血栓形成主要影响供应心脏、大脑和外周的血管,是全球范围内的主要死亡原因。血栓形成的病理生理机制在很大程度上尚不清楚。遗传因素导致 30%的 CVD 发病率。其余的变异可以用生活方式因素来解释,如吸烟、饮食和运动习惯、环境毒素暴露、药物使用和其他合并症。表观遗传变异可以是获得性的,也可以是遗传性的,是基因与环境之间的相互作用。表观遗传学与动脉粥样硬化、缺血/再灌注损伤以及低氧对心血管的反应有关。基因表达的表观遗传调节剂主要是 CpG 岛的甲基化、组蛋白翻译后修饰(PTMs)和 microRNAs(miRNAs)。这些表观遗传调节剂通过激活或沉默来控制基因表达。表观遗传控制大多是动态的,可以潜在地被操纵以防止或逆转基因的失控表达,这种特性使它们成为潜在的治疗靶点。在目前的综述中,我们系统地研究并呈现了来自人类研究的与血栓形成相关的表观遗传改变的现有数据。在几种血栓性疾病中观察到了表观遗传改变的证据,如冠状动脉疾病和脑血管疾病、先兆子痫和抗磷脂综合征。差异 CpG 甲基化和特定的组蛋白 PTMs 控制着促血栓形成和促炎基因的转录,这些基因也与血栓形成和 CVD 的易患因素有关,如吸烟、空气污染、高三酰甘油血症、职业性颗粒物质暴露以及合并症,包括癌症、慢性阻塞性肺疾病和慢性肾脏病。这些临床观察结果得到了体外实验的进一步支持,表明表观遗传调节影响血栓性疾病的病理生理学,具有潜在的诊断或治疗效用。